Clinical Trials

46 enrolled

Leukemia, B-Cell

NCT04605666 2024-08-20

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

77 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT01597219 2024-05-03

UK-Haplo

LymphoidMyeloidOther hematologic neoplasm

77 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05095155 2023-03-14

Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality

Completed

400 enrolled

Lymphoma, Leukemia, B-Cell

NCT04260945 2022-03-08

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

12 enrolled

Leukemia, B-Cell

NCT03068416 2021-10-20

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

24 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT02933320 2021-07-08

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Phase 1/2 Completed

14 enrolled 17 charts

Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Lymphoma, B-Cell

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

66 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01626495 2020-03-23

Pedi CART19

Phase 1/2 Completed

73 enrolled 12 charts

Leukemia, B-Cell, Lymphoma, B-Cell

NCT01279252 2019-01-25

CLEAR

71 enrolled

Leukemia, B-Cell

NCT01805375 2018-02-05

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

28 enrolled

Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell

NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

34 enrolled

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02132624 2017-10-30

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Phase 1/2 Completed

15 enrolled

Leukemia, B-Cell, Lymphoma, B-Cell

NCT01362452 2017-08-03

Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells

5 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00201721 2017-02-08

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

28 enrolled

Leukemia, B-Cell

NCT00990587 2015-06-22

Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

20 enrolled

Anemia, Refractory, with Excess of Blasts, Blast Crisis, Hodgkin Disease, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00230282 2014-10-06

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia

25 enrolled 7 charts

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00558181 2010-02-23

LT-CLL-001

29 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00292760 2009-12-16

A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion